Nintedanib, a small-molecule FGFR/PDGFR/VEGFR TKI, demonstrated efficacy in clinical trials against lung cancer and is approved for second-line treatment of lung adenocarcinoma [15]. This evidence concerns the gene KDR and lung cancer.